Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy
Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determinat...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-03-01
|
| Series: | Open Heart |
| Online Access: | https://openheart.bmj.com/content/12/1/e003192.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|